Tools
Stock profile

UNITED THERAPEUTICS Corp (UTHR)

UTHR · Latest close $577.34 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$577.34
As of Nov 18, 2026
Tracked funds holding
4 of 149
2026 Q2 13F filings
Opened / added
1 / 2
vs previous quarter
Trimmed / exited
2
vs previous quarter

UNITED THERAPEUTICS Corp (UTHR) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 2 funds adding, and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $349.7M sold). Latest close $577.34 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 17, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-349.7M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Insider trading · 5% holders · Politician trading · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Avoro Capital Advisors · Deerfield Management · Deep Track Capital — 4 tracked funds hold UTHR. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 867 sales ($349.7M). Insider trading

Often held alongside

HEMAB THERAPEUTICS HOLDINGS (COAG) · VERA THERAPEUTICS INC (VERA) · XENON PHARMACEUTICALS INC (XENE) · STRUCTURE THERAPEUTICS INC (GPCR) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Avoro Capital Advisors13.52%2,777,777ADDED (+5.6%) Q3 filed Nov 16
Deerfield Management2.58%457,000HELD Q3 filed Nov 16
Deep Track Capital0.97%123,616NEW Q3 filed Nov 16
Axiom Investors0.26%54,437ADDED (+6662.4%) Q3 filed Nov 12
Mairs & Power Funds——EXITED
Avoro Capital Advisors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +6.8% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

608.49261.352024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding874 of 8,857 filers
Long-only filers among them873
Change vs 2026 Q1+36 net · 792 entered · 756 exited
Shares reported, all filers41,446,694
Reported value, all filers$22.4B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$3.2B
Net income · FY2025$1.3B
Total assets · FY2025$7.9B
Shares outstanding42,890,692
Market cap (at latest close)$24.8B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 29, 2026.

Short interest

Shares short · Oct 15, 20262,457,723
Share of shares outstanding5.73%
Days to cover2.57

Shares short at recent settlements — Jul 31, 2026: 2.3M · Aug 14, 2026: 2.1M · Aug 31, 2026: 2.1M · Sep 15, 2026: 2.8M · Sep 30, 2026: 3.6M · Oct 15, 2026: 2.5M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 867 sales by 4 insiders ($349.7M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell373$576.16$214.9KSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell1,017$577.14$586.9KSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell1,763$578.17$1.0MSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell1,127$579.11$652.7KSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell955$580.13$554.0KSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell1,112$581.18$646.3KSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell449$582.57$261.6KSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell2,004$583.22$1.2MSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell381$584.22$222.6KSEC filing
Nov 17, 2026ROTHBLATT MARTINE AChairperson & CEOSell79$585.27$46.2KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026ROTHBLATT MARTINE ASC 13G/A2,333,7215.3%Jun 30, 2026SEC filing
Aug 13, 2026Wellington Management Group LLPSC 13G/A1,379,0253.2%Jun 30, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G2,278,3485.2%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 10, 2026Wellington Management Group LLPSC 13G2,441,4925.7%Dec 31, 2025SEC filing
May 12, 2025Wellington Management Group LLPSC 13G/A2,026,4164.5%Mar 31, 2025SEC filing
Feb 10, 2025Wellington Management Group LLPSC 13G/A2,463,8915.5%Dec 31, 2024SEC filing
Feb 5, 2025STATE STREET CORPORATIONSC 13G2,199,9944.9%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Government relations

Lobbying: 15 Lobbying Disclosure Act filings named this company as client, 2008–2026; most common issues: Science/Technology (7), Pharmacy (7), Defense (6).

Federal contracts: $7.9M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$1.1M
FY2022$1.3M
FY2023$1.8M
FY2024$2.0M
FY2025$501.2K
FY2026$1.2M

Largest awards collected

Award IDAgencyAmountStart
36C24122N0162Department of Veterans Affairs$366.3KDec 7, 2021
36C26123N0607Department of Veterans Affairs$298.6KMay 19, 2023
36C26022F0036Department of Veterans Affairs$296.0KNov 1, 2021
36C26124N0362Department of Veterans Affairs$264.5KJan 5, 2024
36C24121F0275Department of Veterans Affairs$207.7KAug 5, 2021

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Piotroski — Financial health improved over the past year

· O'Neil CAN SLIM — Explosive earnings growth leaders

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Key figures

· Buffett — Latest ROE: 18.8% · Years ROE ≥15% (of 10): 8 · 10-yr avg ROE: 17.2% · Latest net income: $1.3B

· Growth — Latest revenue: $3.2B · 5-yr revenue CAGR: 16.5% · Straight growth years: 6

· Graham — Current ratio: 6.60 · Straight profitable years: 6 · Debt ratio: 0.11 · Latest net income: $1.3B

· Piotroski — F-score: 8 · Return on assets: 16.9% · Operating cash flow: $1.6B

· O'Neil CAN SLIM — 3-yr EPS growth: 22.9% · ROE: 18.8% · Latest revenue growth: 10.6%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.09 · Operating cash flow: $1.6B · Net income: $1.3B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold UTHR — ranked by lift, the co-holding pattern described in Methodology: HEMAB THERAPEUTICS HOLDINGS (COAG) · VERA THERAPEUTICS INC (VERA) · XENON PHARMACEUTICALS INC (XENE) · STRUCTURE THERAPEUTICS INC (GPCR).

Recent 8-K filings

FiledItemsSource
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 22, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Oct 14, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

HEMAB THERAPEUTICS HOLDINGS (COAG) · Track Record: how the signals scored · Practice timing on UTHR

One email a week: the week’s new filings and research. Subscribe free

← UTG  ·  UTI →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.